Douglas Wilmot Ball
Associate Professor
Medicine - Endocrinology, Diabetes and Metabolism
Johns Hopkins Medicine
United States of America
Biography
Dr. Douglas Ball is an associate professor of medicine at the Johns Hopkins University School of Medicine. He holds a joint appointment in oncology. His areas of clinical expertise include diagnostic radiology, endocrine oncology, thyroid cancer and thyroid diseases. Dr. Ball earned his M.D. from the George Washington University School of Medicine. He completed his residency at the University of Pittsburgh-Presbyterian University Hospital and performed a fellowship in endocrinology and metabolism at Johns Hopkins.
Research Interest
medullary thyroid cancer; differentiated thyroid cancer; anaplastic thyroid cancer
Publications
-
Elisei R, Schlumberger M, Mueller S, Schoffski P, Brose M, Shah M, Licitra L, Jarzab B, Medvedev V, Kreissl M, Niederle B, Cohen E, Wirth L, Ali H, Hessel C, Yaron Y, Ball D Nelkin B, Sherman S. Cabozantinib in Progressive Medullary Thyroid Cancer. J Clin Oncol, 31:3639-46, 2013.
-
Jin N, Jiang T, Rosen DN, Nelkin BD, Ball DW . Synergistic action of a RAF inhibitor and dual PI-3 Kinase / mTOR inhibitor in thyroid cancer. Clin Can Res 17:6482-9, 2011.
-
Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball DW, Doyle LA, Chen H, Ye X, Azad N. A Phase I trial of vertical inhibition of IGF signaling using cixutumumab, an anti-IGF1-R antibody, and selumetinib, a MEK 1/2 inhibitor, in patients with advanced solid tumors, British Journal of Cancer, 2014,
-
Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts N, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SPA, Toledo RA, Morris LGT, Ghossein R, Fagin JA, Chan TA, Velculescu VA, Vogelstein B, Kinzler KW, PapadopoulosN, Nelkin BD, and Ball DW. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 98:E364-9, 2013.
